CurrentBlue Cross Blue Shield - MassachusettsPolicy N/A

Prescription digital therapeutic devices (Freespira, NightWare)

This policy covers the use and coverage stance for specified prescription digital therapeutics (software as a medical device) including Freespira and NightWare for treatment of panic disorder, PTSD, and nightmare disorder for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyPrescription digital therapeutic devices (Freespira, NightWare)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateSep 1, 2023

Next Review DateSep 1, 2024

Key ActionObtain precertification/preauthorization for inpatient procedures described in this policy; outpatient use is not covered for several product types.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2devices discussed

A9291investigational HCPCS

Insufficientevidence status

Nationalevaluation framework

Coverage determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Device-specific investigational determinations

Coverage stance for the named devices

Freespira: Use of Freespira is considered investigational for all indications including treatment of panic disorder and/or post-traumatic stress disorder (PTSD).

Evidence consists of single-arm studies with high loss to follow-up (24%–58%) and other limitations; insufficient evidence that a 4-week respiratory biofeedback program improves net health outcome.

NightWare: Use of NightWare is considered investigational for nightmare disorder or nightmares from PTSD.

Pivotal randomized trial did not meet its primary efficacy endpoint and was likely underpowered; evidence insufficient to demonstrate improvement in net health outcome.

For outpatient settings, the services described in this policy are not a covered service for the following product types: Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM. Providers should refer to the member's contract benefits to determine coverage for individual members.

Both Freespira and NightWare are determined to be investigational. For Freespira, the evidence consists primarily of single-arm studies with high loss to follow-up and methodological limitations; therefore the benefit of the 4-week respiratory biofeedback program is uncertain. For NightWare, the pivotal trial did not meet its primary efficacy endpoint and was likely underpowered. Overall, the available evidence is insufficient to demonstrate an improvement in net health outcome, and use of these technologies is not supported as medically necessary.

Authorization, documentation, and billing guidance

Prior Authorization

Prior Authorization Required

Precertification/prior authorization is required when the procedure is performed inpatient. Outpatient use is not covered for several product types — check the member's contract for benefit-specific coverage.

Precertification/prior authorization IS_REQUIRED for all products if the procedure is performed inpatient.
Outpatient services: not a covered service for Commercial PPO and Indemnity, Medicare HMO Blue, Medicare PPO Blue (verify specific product names and member benefits).
Verify member contract benefits and product-specific coverage before scheduling.

Documentation Required

Coding and Documentation Requirements

Report all services using current industry-standard codes and include appropriate modifiers and diagnosis codes. Maintain contemporaneous clinical documentation that supports the medical necessity of the service.

Use the most up-to-date CPT/HCPCS/ICD-10 and revenue codes when billing.
Include applicable modifiers and supportive documentation with the claim.
Retain clinical records that justify the level of care and that would be provided on request for audit or medical review.

Denial Risk

Authorization and Coverage Limitations — Provider Actions

Actions that may prevent claim denials or delays: obtain required authorizations before inpatient procedures, confirm outpatient coverage for the member's specific product, and submit fully coded claims with supporting documentation.

If authorization is required but not obtained for an inpatient admission, the claim may be denied or payment reduced.
Outpatient procedures listed as “not covered” for the member's product should not be submitted without prior confirmation of coverage.
Attach clinical records and authorization reference numbers to expedite review.

Context and scope

Digital health technologies, including prescription mobile applications and software as a medical device (SaMD), are being evaluated as therapeutic interventions for behavioral health conditions. Freespira is a clinician-prescribed respiratory biofeedback program intended to regularize breathing over a 4-week training period for panic disorder and PTSD-related panic symptoms. NightWare is a wearable-based intervention designed to reduce nightmare disorder or PTSD-associated nightmares. This policy reviews FDA-cleared/approved SaMD prescribed by clinicians and assesses published evidence for clinically meaningful benefits and net health outcomes.

Key definitions

SaMD — Software as a Medical Device

DefinitionSoftware as a Medical Device (SaMD): software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device.

Scope inclusion criteriaTo be considered under this policy, the software must meet the SaMD definition, have received FDA marketing clearance or approval (de novo, 510(k), or PMA), and be prescribed by a healthcare provider.

Examples (non‑exclusive)Standalone therapeutic software (eg, apps or cloud‑based programs that provide a therapeutic intervention independent of a hardware medical device).

ExclusionsSoftware used in the manufacture or maintenance of a medical device, or software integral to a hardware device (eg, firmware that drives infusion pump motors) are outside this SaMD scope.

Evaluation frameworkSaMDs are evaluated using the BCBSA/technology evaluation criteria: regulatory approval, evidence of improved net health outcomes vs alternatives, real‑world usability, and HIPAA protections.

Named therapies and devices

Respiratory biofeedback (Freespira)

Respiratory biofeedback (Freespira): Freespira is intended to regularize breathing through capnometry-guided biofeedback over a 4-week training period for individuals with panic symptoms (panic disorder) and PTSD-related panic symptoms. Existing evidence comprises single-arm studies reporting symptom improvement but is limited by high loss to follow-up and lack of control groups; therefore benefit is uncertain and the evidence is insufficient to demonstrate improvement in net health outcome.4-week program

Single-arm studies with 24%–58% loss to follow-up; randomized controlled trial evidence lacking.

Wearable intervention for nightmares (NightWare)

Wearable intervention for nightmares (NightWare): NightWare is a wearable-based intervention intended for nightmare disorder or PTSD-associated nightmares. The single pivotal randomized trial did not meet its primary efficacy endpoint and was likely underpowered; available evidence is insufficient to determine an improvement in net health outcome.

Pivotal trial failed to meet primary endpoint and had recruitment/ power limitations.